TITLE

Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy

AUTHOR(S)
Papayannakos, C; Daniel, R
PUB. DATE
June 2013
SOURCE
Gene Therapy;Jun2013, Vol. 20 Issue 6, p581
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Replication-deficient retroviruses have been successfully utilized as vectors, offering an efficient, stable method of therapeutic gene delivery. Many examples exist proving this mode of integrative gene transfer is both effective and safe in cultured systems and clinical trials. Along with their success, severe side effects have occurred with early retroviral vectors causing a shift in the approach to vector design before further clinical testing. Several alternative delivery methods are available but lentiviral vectors (LV) are among the most favorable as they are already well understood. LV offer safer integration site selection profiles and a lower degree of genotoxicity, compared with γ-retroviral vectors. Following their introduction, development of the self-inactivating vector configuration was a huge step to this mode of therapy but did not confer full protection against insertional mutagenesis. As a result integration, modeling must be improved to eventually avoid this possibility. The cellular factor LEDGF/p75 seems to play an essential role in the process of LV site selection and its interactions with chromatin are being quickly resolved. LEDGF/p75 is at the center of one example directed integration effort where recombinant products bias the integration event, a step toward fully directed integration into pre-determined benign loci. A more accurate picture of the details of LEDGF/p75 in the natural integration process is emerging, including new binding specificities, chromatin interaction kinetics and additional cellular factors. Together with next-generation sequencing technology and bio-informatics to analyze integration patterns, these advancements will lead to highly focused directed integration, accelerating wide-spread acceptance of LV for gene therapy.
ACCESSION #
87970060

 

Related Articles

  • Gene Therapy for Rheumatoid Arthritis. Fabre, Sylvie; Apparailly, Florence // BioDrugs;2011, Vol. 25 Issue 6, p381 

    Rheumatoid arthritis (RA) was one of the earliest targets for gene therapy. Since the first clinical trial involving gene therapy in RA was initiated in 1996, eight clinical trials have been conducted assessing gene therapy in RA. Gene therapy has benefited from advances in biologics in terms of...

  • Mechanisms Governing Lentivirus Integration Site Selection. Ciuffi, Angela // Current Gene Therapy;Dec2008, Vol. 8 Issue 6, p419 

    An essential step of the life cycle of retroviruses is the stable insertion of a copy of their DNA genome into the host cell genome, and lentiviruses are no exception. This integration step, catalyzed by the viral-encoded integrase, ensures long-term expression of the viral genes, thus allowing...

  • Retroviral Vector-mediated Gene Therapy for Metabolic Diseases: An Update. Ferry, Nicolas; Pichard, Virginie; Bony, Dominique Aubert S�bastien; Nguyen, Tuan Huy // Current Pharmaceutical Design;8/11/2011, Vol. 17 Issue 24, p2516 

    Retroviral vectors have been used for several decades for the transfer of therapeutic genes to various cells or organs including the liver. Initial studies aimed at treating inherited liver deficiencies were carried out with murine oncoretroviral vectors either delivered directly to the organ or...

  • Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Witting, S R; Vallanda, P; Gamble, A L // Gene Therapy;Oct2013, Vol. 20 Issue 10, p997 

    Lentiviruses are becoming progressively more popular as gene therapy vectors due to their ability to integrate into quiescent cells and recent clinical trial successes. Directing these vectors to specific cell types and limiting off-target transduction in vivo remains a challenge. Replacing the...

  • Mouse Transplant Models for Evaluating the Oncogenic Risk of a Self-Inactivating XSCID Lentiviral Vector. Zhou, Sheng; Ma, Zhijun; Lu, Taihe; Janke, Laura; Gray, John T.; Sorrentino, Brian P. // PLoS ONE;Apr2013, Vol. 8 Issue 4, p1 

    : Hematopoietic stem cell gene therapy requires the use of integrating retroviral vectors in order to stably transmit a therapeutic gene to mature blood cells. Human clinical trials have shown that some vector integration events lead to disrupted regulation of proto-oncogenes resulting in...

  • Lentiviral Vectors for Gene Therapy of HIV-1 Infection. Mautino, Mario R. // Current Gene Therapy;Feb2002, Vol. 2 Issue 1, p23 

    Lentiviral vectors based on HIV-1, HIV-2, or SIV have the ability to transduce dividing and non-dividing T cells, dendritic cells, hematopoietic stem cells and macrophages, which are the main target cells for gene therapy of HIV-1 infection. Besides their function as gene delivery vehicles,...

  • Lentiviral Vectors. Verma, Inder // Nature Biotechnology;Nov99 Supplement 4, Vol. 17, p7 

    Focuses on the drawbacks in gene therapy approaches due to the lack of an efficient gene delivery system. Limitations of retroviral and adenoviral vectors in ex vivo gene delivery; Creation of lentiviral vectors to overcome deficiencies of the therapy.

  • Gene Therapy of HIV-1 Infection Using Lentiviral Vectors Expressing Anti-HIV-1 Genes. Mautino, Mario R.; Morgan, Richard A. // AIDS Patient Care & STDs;Jan2002, Vol. 16 Issue 1, p11 

    The use of vectors based on primate lentiviruses for gene therapy of human immunodeficiency virus type 1 (HIV-1) infection has many potential advantages over the previous murine retroviral vectors used for delivery of genes that inhibit replication of HIV-1. First, lentiviral vectors have the...

  • A trial of somatic gene targeting in vivo with an adenovirus vector. Ino, Asami; Naito, Yasuhiro; Mizuguchi, Hiroyuki; Handa, Naofumi; Hayakawa, Takao; Kobayashi, Ichizo // Genetic Vaccines & Therapy;2005, Vol. 3, p1 

    Background: Gene targeting in vivo provides a potentially powerful method for gene analysis and gene therapy. In order to sensitively detect and accurately measure designed sequence changes, we have used a transgenic mouse system, MutaMouse, which has been developed for detection of mutation in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics